CurvaFix closed a $39 million equity financing. The company also announced that Mark Foster has been named CEO, succeeding founder and current CEO Steve Dimmer, who will transition into a strategic advisory role.
Proceeds from the financing will be used to expand the treatment of Fragility Fractures of the Pelvis (FFP) throughout the U.S. with the nationwide launch of the CurvaFix IM Implant.
Mark Foster is an experienced C-Suite executive with a broad background in the healthcare, medical device, and pharmaceutical industries. Before joining CurvaFix, Foster was president and CEO of Trice Medical, a player in the field of minimally invasive orthopedic procedures. Formerly he was V.P. of U.S. Sports Medicine Business for Smith+Nephew and also held leadership roles at Boston Scientific.
“I have had the opportunity to observe the successful implementation and adoption of CurvaFix IM Implants in the orthopedic pelvic fracture fixation market, for which Steve has played a pivotal role in taking the company to this point,” Foster said. “I am looking forward to leading the CurvaFix team in scaling CurvaFix’s technology to benefit many more patients, physicians, and payers.”
“It has been a privilege to lead CurvaFix from concept through commercialization to where it is today, and I am honored to pass off the reins to Mark for this next exciting phase of CurvaFix’s growth,” said Dimmer.
CurvaFix closed a $39 million equity financing. The company also announced that Mark Foster has been named CEO, succeeding founder and current CEO Steve Dimmer, who will transition into a strategic advisory role.
Proceeds from the financing will be used to expand the treatment of Fragility Fractures of the Pelvis (FFP) throughout the U.S. with...
CurvaFix closed a $39 million equity financing. The company also announced that Mark Foster has been named CEO, succeeding founder and current CEO Steve Dimmer, who will transition into a strategic advisory role.
Proceeds from the financing will be used to expand the treatment of Fragility Fractures of the Pelvis (FFP) throughout the U.S. with the nationwide launch of the CurvaFix IM Implant.
Mark Foster is an experienced C-Suite executive with a broad background in the healthcare, medical device, and pharmaceutical industries. Before joining CurvaFix, Foster was president and CEO of Trice Medical, a player in the field of minimally invasive orthopedic procedures. Formerly he was V.P. of U.S. Sports Medicine Business for Smith+Nephew and also held leadership roles at Boston Scientific.
“I have had the opportunity to observe the successful implementation and adoption of CurvaFix IM Implants in the orthopedic pelvic fracture fixation market, for which Steve has played a pivotal role in taking the company to this point,” Foster said. “I am looking forward to leading the CurvaFix team in scaling CurvaFix’s technology to benefit many more patients, physicians, and payers.”
“It has been a privilege to lead CurvaFix from concept through commercialization to where it is today, and I am honored to pass off the reins to Mark for this next exciting phase of CurvaFix’s growth,” said Dimmer.
Copy to clipboard 
